p42/p44 mitogen-activated protein kinases inhibit atrial natriuretic peptide mRNA transcription in gp130-mediated hypertrophic ventricular myocytes  by Dong, Zhan-Ling et al.
216 Asian Pacific Journal of Tropical Medicine (2014)216-220
Document heading          doi: 10.1016/S1995-7645(14)60024-9 
p42/p44 mitogen-activated protein kinases inhibit atrial natriuretic 
peptide mRNA transcription in gp130-mediated hypertrophic 
ventricular myocytes
Zhan-Ling Dong1#, Yang Wang1#, Tian-Fa Li1, Shao-Jiang Zheng1, Yue-Qiong Kong1, You-
Ling Lan1, Jun-Li Guo1*, Shi-Gan Fu1,2*
1Department of Physiology and Cardiovascular Institute, Hainan Medical College, Haikou 571199, PR China
2Department of Physiology, Hainan Provincial Health School, Haikou 570311, PR China
 Contents lists available at ScienceDirect
Asian Pacific Journal of Tropical Medicine
journal homepage:www.elsevier.com/locate/apjtm
ARTICLE INFO                           ABSTRACT
Article history:
Received 10 December 2013
Received in revised form 15 January 2014
Accepted 15 February 2014
Available online 20 March 2014
Keywords:
Cardiomyocytes
Hypertrophy
Atrial natriuretic peptide
  *Corresponding author: Shi-Gan Fu and Jun-Li Guo, Department of Physiology and 
Cardiovascular Institute, Hainan Medical College, Haikou 571199, PR China. 
     Tel: +86-898-66893740; Fax: +86-898-66893170
     E-mail: fushigan@aliyun.com and guojl79@163.com
    Foundation project:This work was supported by a grant from the National Natural 
Science Foundation of China (30260032, 81000073 and 81160020), Key Program of 
Science and Technology of Hainan Province (061011 and ZDXM20100045), Education 
Department of Hainan Province (Hj2007113), Natural Science Foundation of Hainan 
Province (310043 and 811197) and Key Project of Chinese Ministry of Education 
(212137) and HJHZ2013-06. 
     #: Both authors contributed equally to this work.
1. Introduction
  Under normal physiological circumstances, atrial 
natriuretic peptide (ANP) is almost exclusively found 
in the atrium and is only in the ventricle during 
embryonic development. During periods of sustained 
increase in blood pressure and associated compensatory 
left ventricular hypertrophy, ANP is induced more in 
ventricular myocardial cells. Overexpression of ANP is 
an adaptation of cardiomyocyte, and  multiple evidence 
has shown that increasing expression of ANP is associated 
with the inhibition of hypertrophy[1,2]. ANP inhibits 
cardiomyocyte size increase and protein synthesis in 
cultured cardiomyocyte when stimulated by angiotensin 
II or endothelin 1 (ET-1)[3,4]. Evidence for ANP inhibition 
has also been observed in genetic models of spontaneous 
hypertension and related conditions of pressure and 
volume overload. The adaptation of myocardium is initially 
associated with an increase in gene transcription of ANP in 
vivo[5-7]. 
  The mitogen-activated protein kinase (MAPK) is a family 
of serine-threonine protein kinases that are activated by a 
number of extracellular stimuli. Three major subfamilies 
have been characterized, including extracellular signal-
regulated kinase (ERK), also called p42/44 MAPK, p38 
MAPK, and JNK, which mediate downstream effects via 
activation of appropriate transcription factors and play role 
in cellular roliferation, differentiation, and apoptosis[8,9]. 
Objective: To understand the role of ANP mRNA transcription regulation in gp130-mediated 
cardiomyocyte hypertrophy, and the involved mitogen-activated protein kinase kinase (MEK)-
extracellular signal-regulated kinase (ERK, also called p42/p44 MAPK) signaling pathway. 
Methods: Isolated neonatal ventricular myocytes were treated with different concentrations of 
CT-1 (10-9, 10-8 and 10-7 mol/L). MTT was used to analyze the viability and RT-PCR was used to 
detect ANP mRNA levels in cardiomyocyte. To inhibit p42/p44 MAPK activity in hypertrophic 
cardiomyocytes, the cells were pretreated with a specific MEK1 inhibitor. Results: CT-1 
significantly induced ANP mRNA expression and the viability of cardiomyocytes in a dose- 
and time-dependent manner. Furthermore, blocking p42/p44 MAPK activity by the special 
MEK1 inhibitor upregulated the ANP mRNA. Conclusions: p42/p44 MAPK have an important 
role in suppressing ANP mRNA transcription and cell activity in gp130-mediated hypertrophic 
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Although it has been reported that p38 MAPK pathway 
is involved in ANP transcription[10], furthermore, MAPK 
kinase (MEK) and p42/p44 MAPK are potential activators of 
hypertrophy[9,11], little is known as to whether p42/p44 MAPK 
is involved in the expression of ANP gene. 
  Cardiotrophin-1(CT-1), as a 21.5 kDa protein, was identified
by expression cloning based on its ability to induce 
cardiomyocyte hypertrophy, and characterized as a member 
of the IL-6 family and a factor to induce cardiomyocyte 
hypertrophy[12,13].
  The binding of CT-1 to its receptor activates Janus kinases 
(JAKs) which then phosphorylate gp130, producing binding 
sites for proteins with scr homology 2 (SH2) domains, such as 
growth factor receptor bound protein2 (GRB2). This is then 
the starting point for a Ras/Raf/MEK/ERK/p90 RSK cascade 
[14]. 
  In this study, CT-1-stimulated hypertrophic ventricular 
myocytes were used for studying ANP mRNA transcription 
under the suppression of the MEK/ERK (p42/p44 MAPK) 
pathway.
2. Materials and methods 
2.1. Chemical compounds and reagents 
  Dulbecco’s modified eagle medium (DMEM) medium 
(Boehringer Mannheim GmbH) prepared with positive 
pressure filtration sterilization and adjusted to pH 7.2 was 
kept at 4 曟. D-Hanks plus enzyme solution was prepared 
with pancreatin (DIFCOTM, Becton Dickinson and Company; 
dilution 1:250), diluted to 0.8 g/L (pH 7.2, Ca2+ and Mg2+ 
free), filtrated through a microporous membrane (0.22 毺m) 
and stored at -20 曟. 5-Bromodeoxyuridine (BrdU, SERVA 
Co. Ltd) was diluted to 10 mmol/L, then filtrated through 
a microporous membrane and stored at -20曟. 3-(4,5-
dimethyl-thiazol-2-yl)-2,5-diphenyl-2H-tetrazolium 
bromide (MTT) (Sigma- Aldrich, St Louis, MO, United States) 
was dissolved at a concentration of 5 mg/mL in DMSO. MEK/
ERK1/2 activation inhibitor (PD098059, Sigma-Aldrich Co.) 
was prepared at a concentration of 5 mmol/L. Calphostin C 
(Cal C, a PKC inhibitor, Sigma-Aldrich Co.) was prepared 
at a concentration of 1 mmol/L. CT-1 (Alomone Labs Ltd., 
Jerusalem, Israel) was prepared at 5 mmol/L, 1 mmol/L and 
10 毺mol/L. 
  RNA extraction reagents were TRIzol reagent (Life 
Technologies, Carlsbad, CA, USA), lower melting point 
agarose (Promega Co., Madison, WI, USA); Tris-boric acid 
(TBE) electrophoresis buffer (10伊): 108 g Tris base, 55 g 
boric acid and 40 mL of 0.5 mol/L EDTA, pH 8.0; 10 mg/mL
ethidium bromide (Sigma-Aldrich Co.). Before use, the 
agarose was diluted in 1伊TBE.
2.2. Neonatal ventricular myocytes preparation and culture 
  Primary cultures of ventricular myocytes were prepared 
from 1-day-old Sprague-Dawley neonatal rats using an 
established lab protocol. The isolation procedure uses 0.8 g/L
pancreatin, pH 7.2 (DIFCOTM, Becton Dickinson and 
Company, Franklin Lakes, NJ, USA) and 0.08% trypsin 
solution for 10 min to produce separated cells, which were 
seeded on glass coverslips (3 mm diameter), and beat 
spontaneously. Cells were incubated at 37 曟 in air with 
5% CO2 and 98% humidity. The culture medium (DMEM) 
was changed every other day. After incubation, ventricular 
myocytes were seeded at a density of 3伊106 cells/mL in 25-
mL culture flasks. Culture media were initially treated 
with 0.1 mmol/L bromodeoxyuridine (BrdU) for inhibition 
of non-cardiomyocyte proliferation. All rats were treated 
according to the Regulations for the Administration of 
Affairs Concerning Experimental Animals (State Science and 
Technology Commission, People’s Republic of China).
2.3. Colorimetric MTT cell viability assay
  The colorimetric MTT assay was used to assess the viability 
of isolated ventricular myocytes. After treatment with 
different concentrations of CT-1, hypertrophic ventricular 
myocytes mixed with 10 毺L of MTT (5 mg/mL) were 
incubated for 4 h at 37 曟 and 5% CO2 (myocyte density was 
10
5 cell/L). Then, 150 毺L of DMSO (0.05 mol/L) were added 
with vibration for 10 min. The optical density (OD) value of 
each well was measured by a microplate spectrophotometer 
(Multiskan EX Primary EIA V.2.1-1) using a test wavelength 
of 570 nm and a reference wavelength of 630 nm. 
 
2.4. Extraction of total RNA from cultured ventricular 
myocytes and RT-PCR
  Cultured ventricular myocytes were treated with 1 mL of 
TRIzol reagent for 5 min at room temperature. Purified total 
RNA was measured with an ultraviolet spectrophotometer 
by adjusting the OD260/OD280 ratio between 1.8 and 2.0. RNA 
concentrations were calculated by spectrophotometry at 
OD260. 2 毺g of total RNA was used as template to generate 
first strand cDNA by random priming using Promega RT 
System. ANP primers were: forward 5’-CAT CAC CAT 
CTT CCA GGA GCC-3’; reverse 5’-CCC CGC TTC ATC 
GGT CTG-3’ (cDNA fragment with an amplified length of 
186 bp). GAPDH was used as an internal control with the 
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following primers: forward 5’-CAT CAC CAT CTT CCA GGA 
GCC-3’; reverse 5’-TGA CCT TGC CCA CAG CCT TG-3’ 
(cDNA fragment with an amplified length of 443 bp). The 
products of PCR were separated by 1.5%-2.0% agarose 
gel electrophoresis 0.5% (w/v) ethidium bromide (EB) and 
visualized under UV using gel imaging system (Bio-Rad Gel 
Doc1000, Bio-Rad). The ANP cDNA to GAPDH cDNA ratio 
was calculated based on the optical density of the bands. All 
measurements were repeated three times.
2.5. Statistical analysis
  All results are presented as mean依standard error of the 
mean (SEM). All statistical analyses were performed using 
Sigma Plot for Windows, Version 10.0 (Systat Software, INC). 
Differences between experimental groups were analyzed 
using the Mann-Whitney U-Test. Values of P<0.05 between 
groups were considered significant.   
3. Results
3.1. CT-1 induced neonatal ventricular myocytes hypertrophy 
and viability
  Compared with control ventricular myocytes on day 
3, there was no change in the surface area of CT-1-
treated ventricular myocytes at 10-10 mol/L (Figure 1A), 
but it increased when the cells were treated with 10-9 mol/
L CT-1 (Figure 1B). A significant increase was observed 
with concentrations of 10-8 and 10-7 mol/L (Figure 1C and 
D, respectively) on day 3. Further studies revealed that 
the effect of CT-1 on cardiomyocytes viability was time-
dependent by the MTT assay (Figure 1E). Moreover, when 
ventricular myocytes were incubated with 1伊10-9, 10-8 or 
10
-7 mol/L CT-1 for 72 h, significant differences were found 
compared with the control group (Figure 1F), and the effect 
was dose-dependent. 
3.2. ANP mRNA expression in CT-1-induced hypertrophic 
ventricular myocytes 
  After a 24 h incubation with serum-free DMEM, ventricular 
myocytes were incubated with 10-9, 10-8 or 10-7 mol/L CT-1. 
In the control group D-Hanks solution was added instead of 
CT-1. Total RNA was amplified by RT-PCR and ANP mRNA 
levels were analyzed. ANP mRNA levels increased to 146% 
and 213% in ventricular myocytes that were treated with 10-8 
and 10-7 mol/L CT-1, respectively (Figure 2A and C). Next, 
total RNA of ventricular myocytes was extracted after 24, 
72 and 120 h incubation with 10-8 mol/L CT-1 and analyzed 
by RT-PCR. The optical densities of the product bands 
were 1.16依0.18, 1.47依0.17 and 1.97依0.24, respectively. A 
significant difference was found between the 72 h group and 
the 120 h group (P<0.01, Figure 2B). 
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Figure 1. A) Isolated, cultured neonatal cardiomyocytes with culture 
medium only (day 3, 40伊). B-D) Cardiomyocytes incubated with 10 -9,
10 -8 or 10 -7 mol/L Cardiotrophin-1 (CT-1) (day 3, 40伊). E) CT-
1(10 -8mol/L) increased cardiomyocyte viability in a time-dependent 
manner. F) CT-1 enhanced cell viability in a dose-dependent 
manner. Control means cells were treated with D-Hanks solution. * 
means P<0.05 vesus control, ** means P<0.01 vesus control , *** 
means P<0.001vesus control. 
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Figure 2. A) ANP mRNA level from ventricular myocytes with CT-
1-mediated hypertrophy (443 bp = GAPDH mRNA band, used as the 
internal control; 186 bp = ANP mRNA band). Lane 1: DNA maker 
(100-1000 bp), lane 2: mRNA from untreated ventricular myocytes; 
lanes 3-5: mRNA from ventricular myocytes treated with 10-7 mol/
L, 10-8 mol/L or 10-9 mol/L CT-1 for 72 h. B) Time course of ANP 
mRNA expression in CT-1(10-8 mol/L)-treated ventricular myocytes. 
Lane 1: DNA maker (100-1 000 bp); Lanes 2, 4, 6: controls (untreated 
cultured myocytes); Lane 3: 24 h treatment with CT-1; Lane 5: 72 
h treatment with CT-1; Lane 7: 120 h treatment with CT-1. C) ANP 
mRNA increased in CT-1-treated cultured cardiomyocytes in a dose-
dependent manner. * means P<0.05 vesus control, ** P<0.01 vesus 
control. 
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3.3. PD098059 inhhibited MEK/ERK pathway to increase 
ANP mRNA expression and cell viability in cultured 
cardiomyocytes
  To explore whether CT-1 induced ANP mRNA upregulation 
through the MEK/ERK-dependent pathways in ventricular 
myocytes, the specific inhibitor PD098059, was tested for 
the effect on CT-1-mediated ANP mRNA expression. To 
compare effects of different pathways, a protein kinase C 
(PKC) inhibitor calphostin C was used.Ventricular myocytes 
were pretreated with 5 mmol/L PD098059 or 1 mmol/L 
calphostin C for 30 min, followed by incubation with 10-8 
mmol/L CT-1 for 72 h. The PD098059 group (n=3) showed 
a significant increase in ANP expression (187%) compared 
with the control group (Figure 3A and B). In contrast, the 
calphostin C group showed no significant difference in ANP 
expression compared with the control group (n=3, ANP/
GAPDH ratio was 1.27依0.17 and 1.04依0.17, respectively, 
Figure 3B). 
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Figure 3. Effect of MEK1 inhibitor PD098059 and PKC inhibitor 
calphostin C on the CT-1-induced ventricular myocytes. A) Lane 
1: Maker (100-1 000 bp); Lane 2: cultured myocytes treated with 
calphostin C and CT-1 (10-8 mol/L); Lane 3: cultured myocytes treated 
with PD098059 and CT-1 (10-8 mol/L); Lane 4: control (cultured 
myocytes treated with 10-8 mol/L CT-1 only. B) Quantification of the 
results shown in A, normalized against APDH.  ** means P<0.01 
vesus control. 
4. Discussion
  ANP gene transcription is active both in atrial and 
ventricular myocytes during embryonic and fetal 
development, but is switched off in the ventricular cells 
in the later stages of fetal development. The ANP-(4-28) 
and ANP-(5-28) peptides are the main ones expressed in 
myocardium granules[15]. Normally, only minor amounts 
of ANP are produced in ventricular cells, but it can be 
overexpressed during left ventricular hypertrophy under 
hemodynamic overload of pathogenic or sustained physical 
fitness[16,17]. Previous studies have indicated that ventricular 
cardiomyocyte hypertrophy is associated with activation of 
ANP mRNA transcription, when stimulated by angiotensin, 
epinephrine or endothelin in vivo[18] and in cultured neonatal 
ventricular myocytes in vitro[19]. The expression of ANP 
increases quickly within the initial period of experimental 
mechanical overload[20]. 
  As the factor responsible for initiating hypertrophy during 
continuous stimulation, in the current study, ANP mRNA 
transcription was detected via CT-1-induced hypertrophy. 
CT-1 is known as a IL-6-related cytokines and a potent 
candidate to induce cardiac myocyte hypertrophy. CT-1 
initially binds to membrane receptors that activate JAKs, 
which then phosphorylate gp130, producing binding sites for 
proteins with Src homology 2 (SH2) domains. Then, the Ras/
Raf/MEK/ERK(p42/44 MAPK) /p90RSK cascade is activated, 
and subsequently phosphorylated and translocated into 
the nucleus[21-23]. The result from our study revealed that 
the transcription of ANP mRNA in hypertrophic ventricular 
myocyte is significantly affected by the concerntration and 
incubation time with CT-1. 
  Furthermore, to test the MEK and p42/p44 MAPK signaling 
pathway may also play roles in CT-1-mediated ANP mRNA 
expression, the specific inhibitor of p42/p44 MAPK PD098059 
was used. Our present results showed that inhibition of 
p42/p44 MAPK enhanced the transcription of ANP mRNA, 
wherease, the CT-1-induced ANP mRNA expression can not 
be influenced by calphostin C, a specific inhibitor of PKC.
In conclusion, our study suggests that ANP mRNA 
transcription is inhibited by MEK-induced p42/p44 MAPK 
phosphorylation. Hence, p42/p44 MAPK may act as an 
inhibitor of ANP mRNA transcription in gp130-mediated 
ventricular hypertrophy.
Conflict of interest statement
  We declare that we have no conflict of interest.
References
[1]   Hayashi D, Kudoh S, Shiojima I, Zou Y, Harada K, Shimoyama M, 
et al. Atrial natriuretic peptide inhibits cardiomyocyte hypertrophy 
through mitogen-activated protein kinase phosphatase-1. 
Biochem Biophys Res Commun 2004; 322: 310-319.
Zhan-Ling Dong et al./Asian Pacific Journal of Tropical Medicine (2014)216-220220
[2]   Kishimoto I, Rossi K, Garbers DL. A genetic model provides 
evidence that the receptor for atrial natriuretic peptide 
(guanylylcyclase-A) inhibits cardiac ventricular myocyte 
hypertrophy. Proc Natl Acad Sci USA 2001; 27: 2703-2706. 
[3]   Hayashi D, Kudoh S, Shiojima I, Zou Y, Harada K, Shimoyama 
M, Imai Y, et al. Atrial natriuretic peptide inhibits cardiomyocyte 
hypertrophy through mitogen-activated protein kinase 
phosphatase-1. Biochem Biophys Res Commun 2004; 322: 310-
319.
[4]   O’Tierney PF, Chattergoon NN, Louey S, Giraud GD, Thornburg 
KL. Atrial natriuretic peptide inhibits angiotensin II-stimulated 
proliferation in fetal cardiomyocytes. J Physiol 2010; 588: 2879-
2889.
[5]   Younes A, Boluyt MO, O’Neill L, Meredith AL, Crow MT, 
Lakatta EG. Age-associated increase in rat ventricular ANP gene 
expression correlates with cardiac hypertrophy. Am J Physiol 
Heart Circ Physiol 1995; 269: H1003-H1008.
[6]   Perhonen M, Takala TE, Vuolteenaho O, M?ntymaa P, Leppaluoto 
J, Ruskoaho H. Induction of cardiac natriuretic peptide gene 
expression in rats trained in hypobaric hypoxic conditions. Am J 
Physiol 1997; 273: R344-352.
[7]   Ohta K, Kim S, Hamaguchi A, Miura K, Yukimura T, Iwao H. 
Cardiac hypertrophy-related gene expression in spontaneously 
hypertensive rats: crucial role of angiotensin AT1, Receptor. Jpn J 
Pharmacol 1995; 67: 95-99.
[8]   Nagai N, Klimava A, Lee WH, Izumi-Nagai K, Handa JT. CTGF 
is increased in basal deposits and regulates matrix production 
through the ERK (p42/p44mapk) MAPK and the p38 MAPK 
signaling pathways. Invest Ophthalmol Vis Sci 2009; 50: 1903-
1910. 
[9]   Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, 
Klevitsky R, et al. The MEK1-ERK1/2 signaling pathway 
promotes compensated cardiac hypertrophy in transgenic mice. 
EMBO J 2000; 19: 6341-6350.
[10] Vassilopoulos A, Gaitanaki C, Papazafiri P, Beis I. Atrial 
natriuretic peptide mRNA regulation by p38-MAPK in the 
perfused amphibian heart. Cell Physiol Biochem 2005; 16: 183-
192.
[11] Tu VC, Bahl JJ, Chen QM. Distinct roles of p42/p44(ERK) 
and p38 MAPK in oxidant-induced AP-1 activation and 
cardiomyocyte hypertrophy. Cardiovasc Toxicol 2003; 3: 119-133.
[12] Pennica D, King KL, Shaw KJ, Luis E, Rullamas J, Luoh SM. 
Expression clone of cardiotrophin-1, which induces cardiac 
myocyte hypertrophy. Proc Natl Acad Sci USA 1995; 92: 1142-
1146.
[13] Bristow MR, Long CS. Cardiotrophin-1 in heart failure. 
Circulation 2002; 106: 1430-1432.
[14] Miyake T, Alli NS, Aziz A, Knudson J, Fernando P, Megeney 
LA, et al. Cardiotrophin-1 maintains the undifferentiated state in 
skeletal myoblasts. J Biol Chem 2009; 284: 19679-19693. 
[15] Bialik GM, Abassi ZA, Hammel I, Winaver J, Lewinson D. 
Evaluation of atrial natriuretic peptide and brain natriuretic 
peptide in atrial granules of rats with experimental congestive 
heart failure. J Histochem Cytochem 2001; 49: 1293-1300.
[16] Takemura G, Fujiwara H, Horike K, Mukoyama M, Saito Y, Nakao 
K, et al.. Ventricular expression of atrial natriuretic polypeptide 
and its relations with hemodynamics and histology in dilated 
human hearts. Immunohistochemical study of the endomyocardial 
biopsy specimens. Circulation 1989; 80 :1137-1147.
[17] Scharhag J, Schneider G, Urhausen A, Rochette V, Kramann B, 
Kindermann W. Athlete’s heart: right and left ventricular mass 
and function in male endurance athletes and untrained individuals 
determined by magnetic resonance imaging. J Am Col Cardiol 
2002; 40: 1856-1863.
[18] Lutz M, Jorg F, Rudolf JW, Heimo E. Predominant activation of 
endothelin-dependent cardiac hypertrophy by norepine- phrine 
in rat left ventricle. Am J Physiol Regul Integr Comp Physiol 2002; 
282: R1389-R1394.
[19] Dietz JR. Mechanisms of atrial natriuretic peptide secretion from 
the atrium. Cardiovasc Res 2005; 68: 8-17.
[20] Ruskoaho H. Atrial natriuretic peptide: synthesis, release, and 
metabolism. Pharmacol Rev 1992; 4: 479-602.
[21] Pennica D, Wood WI, Chien KR. Cardiotrophin-1: a 
multifunctional cytokine that signals via LIF receptor gp130 
dependent pathways. Cytokine & Growth Factor Rev 1996; 7: 81-
91. 
[22] Wu L, Zhao L, Zheng Q, Shang F, Wang X, Wang L, et al. 
Simvastatin attenuates hypertrophic responses induced 
by cardiotrophin-1 via JAK-STAT pathway in cultured 
cardiomyocytes.Mol Cell Biochem 2006; 284: 65-71. 
[23] Fahmi A, Smart N, Punn A, Jabr R, Marber M, Heads R. p42/
p44-MAPK and PI3K are sufficient for IL-6 family cytokines/
gp130 to signal to hypertrophy and survival in cardiomyocytes in 
the absence of JAK/STAT activation. Cell Signal 2013; 25: 898-
909. 
